Results 11 to 20 of about 79,270 (300)

Phosphodiesterase Type 5 Inhibitors, Sport and Doping [PDF]

Current Sports Medicine Reports, 2017
Phosphodiesterase type 5 inhibitors (PDE5i) (e.g., sildenafil, tadalafil, vardenafil, and avanafil) are drugs commonly used to treat erectile dysfunction, pulmonary arterial hypertension, and benign prostatic hyperplasia.
Borrione, Paolo, CECI GALANOS, Roberta, Crescioli, Clara, Di Luigi, Luigi, Duranti, Guglielmo, Sabatini, Stefania, Sansone, Andrea, Sansone, Massimiliano, Sgrò, Paolo   +8 more
core   +5 more sources

Why humans need type 5 phosphodiesterase inhibitors [PDF]

International Journal of Andrology, 2005
SummaryErectile dysfunction (ED) is a widespread medical condition affecting millions of males at any age and requiring medical treatment. ED may simply reflect a limit of human physiology, yet ED equates to genetic death and the high prevalence of ED is a clear evolutionary paradox.
CELLERINO, Alessandro, JANNINI E. A.
openaire   +3 more sources

Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia

BMC Research Notes, 2022
Objective To evaluate the efficacy and safety of add-on therapy with the phosphodiesterase type 5 inhibitor tadalafil in Japanese men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with dutasteride.
Daisuke Gotoh, Kazumasa Torimoto, Yosuke Morizawa, Shunta Hori, Yasushi Nakai, Makito Miyake, Kiyohide Fujimoto   +6 more
doaj   +1 more source

Evidence for benefits and risks of tadalafil as a non-prescription medicine: review and evaluation using the Group Delphi technique to achieve consensus amongst clinical experts

Frontiers in Pharmacology, 2023
An evidence-based consensus meeting was held with urologists, a pharmacist and a cardiologist to perform a structured benefit-risk analysis of reclassifying tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor for treatment of erectile dysfunction (ED),
Kurt Miller, Uwe May, Wolf-Dietrich Beecken, Georgios Hatzichristodoulou, Michael Böhm, Stefan Fink   +5 more
doaj   +1 more source

Cardiovascular Effects of Phosphodiesterase Type 5 Inhibitors

The Journal of Sexual Medicine, 2009
ABSTRACT Introduction Phosphodiesterase type 5 (PDE5) inhibitors are widely used as first-line therapy for erectile dysfunction (ED). Their efficacy and safety combined with an increasing understanding of cyclic guanosine monophosphate (cGMP)-regulated mechanisms have triggered a number of attempts to
Charalambos, Vlachopoulos, Nikolaos, Ioakeimidis, Konstantinos, Rokkas, Christodoulos, Stefanadis   +3 more
openaire   +4 more sources

Is phosphodiesterase type 5 inhibitor use associated with condom breakage? [PDF]

, 2009
This is an open access article - Copyright © 2009 by the BMJ Publishing Group Ltd. All rights reserved.We tested the hypothesis that phosphodiesterase type 5 inhibitor (PDE5i) use would be associated with increased likelihood of condom breakage using an
Crosby, RA, Graham, CA, Sanders, SA, Yarber, WL   +3 more
core   +1 more source

COVID-19 and phosphodiesterase enzyme type 5 inhibitors

Journal of Microscopy and Ultrastructure, 2020
COVID-19 pathology is mainly associated to a pulmonary disease which sometimes might result in an uncontrollable storm related to inflammatory diseases which could be fatal. It is well known that phosphodiesterase enzyme type 5 inhibitors (PDE5Is), such as sildenafil, have been successfully developed for the treatment of pulmonary arterial hypertension;
Al-Kuraishy, Hayder M., Al-Gareeb, Ali I., Al-Niemi, Marwa S., Al-Buhadily, Ali K., Al-Harchan, Nasser A., Lugnier, Claire   +5 more
openaire   +3 more sources

DNA single-strand break repair and spinocerebellar ataxia with axonal neuropathy-1 [PDF]

, 2007
DNA single-strand breaks (SSBs) are the commonest DNA lesions arising spontaneously in cells, and if not repaired may block transcription or may be converted into potentially lethal/clastogenic DNA double-strand breaks (DSBs).
Arnaudeau, Avemann, Barzilai, Bendixen, Caldecott, Caldecott, Cheng, Chrencik, Christiansen, Clements, Connelly, Culmsee, Daroui, Date, Davies, Davies, Davies, de Boer, Deng, D’Arpa, El-Khamisy, Flangas, Furuta, Godthelp, Hinz, Holm, Horwitz, Hsiang, Inamdar, Interthal, Interthal, Interthal, K.W. Caldecott, Kroeger, Lanza, Lesher, Liao, Lindahl, Liu, Mol, Moreira, Morris, Nitiss, Nouspikel, O’Driscoll, Parsons, Plo, Pommier, Pommier, Pommier, Poot, Pouliot, Pouliot, Pourquier, Pourquier, Pourquier, Pourquier, Pourquier, Rideout, Ryan, Ryan, S.F. El-Khamisy, Sarkander, Sarkander, Shao, Stewart, Strumberg, Takashima, Taylor, Thompson, van Waardenburg, Vance, Vidal, Vierck, Wang, Whitehouse, Wilson, Wu, Wu, Yan, Yang, Zhou, Zhou   +82 more
core   +1 more source

Comprehensive stability-indicating method development of Avanafil Phosphodiesterase type 5 inhibitor using advanced Quality-by-Design approach

Journal of Analytical Science and Technology, 2020
Avanafil (AV) is the phosphodiesterase (PDE) type 5 inhibitor drug used in erectile dysfunction, having pyrrolidine, pyrimidine, carboxamide, and chlorine as functional groups which can easily break by environmental changes and cause toxicity. Henceforth,
Mital Patel, Charmy Kothari
doaj   +1 more source

The blue pill (sildenafil) and its descendants: an overview

Current Issues in Pharmacy and Medical Sciences, 2017
An increasing number of men around the world suffer from erectile dysfunction (ED). Indeed, according to the sexuality study conducted by Professor Izdebski, 1 out of 10 men in Poland suffers from ED.
Krzanowski Tomasz, Dabkowska Lila, Wujec Monika, Kedzierska Ewa   +3 more
doaj   +1 more source